Pheochromocytoma and Paraganglioma Market to Exhibit Growth at 7.3% CAGR by 2036 Driven by the Advent of Drug Classes Such as SSTR2 analogs, Dopamine Receptor D2 Agonists, TAAs or TSAs, and Others | DelveInsight
The pheochromocytoma and paraganglioma market is steadily evolving after years of dependence on surgery, symptom control, and a narrow range…